An ISO 9001:2008 & GMP certified company  | info@arlakbiotech.com  |  +91-9803023099, 7696263636  |  1800-121-6263 (Toll Free) 

Z-COX TAB


COMPOSITION:

ETORICOXIB 90MG

ETORICOXIB

Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2). This reduces the generation of prostaglandins (PGs) from arachidonic acid.

PHARMACOLOGY
PHARMACODYNAMICS:

Etoricoxib is a COX-2 selective inhibitor (approximately 106 times more selective for COX-2 inhibition over COX-1). Currently it is approved in more than 60 countries worldwide but not in the US, where the Food and Drug Administration (FDA) require additional safety and efficacy data for etoricoxib before it will issue approval.

PHARMACOKINETICS:

  • Absorption: – Bioavailability is 100% following oral administration.
  • Protein Binding: – 92%
  • Metabolism: – Hepatic, primarily via CYP3A4.
  • Half-Life: – 22 Hours

INDICATIONS

  • Treatment of rheumatoid arthritis,
  • Osteoarthritis,
  • Ankylosing spondylitis,
  • Chronic low back pain, acute pain and
  • Gout
Contact Us
close slider